AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 301 min read$BCDA

Altman Peter purchased $1K of BCDA

Altman Peter (President and CEO) purchased 1,000 shares of BioCardia, Inc. (BCDA) at $1.03 on 2026-09-29.

Original reporting
SEC EDGAR · Altman Peter
Published Sep 30, 2026, 10:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BCDA
Neutral
low confidence
Mentioned
$BCDA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCDANeutralLow
01

Why it matters

The transaction is too small to affect market pricing but confirms the CEO's continued ownership.

02

Market read

Limited relevance; likely no immediate trading opportunity.

03

What to watch

Potential upcoming corporate events or financing needs that prompted the insider to increase his stake.

Relevance 4/10Novelty 3/10Timing: after market close

Background

Form 4 filing discloses a $1,030 insider purchase by BioCardia's CEO.

Company-level read

Ticker impact

$BCDANeutralLow confidence
Context

CEO Altman Peter bought 1,000 shares at $1.03 each, total $1,030, increasing his stake to 384,885 shares.

Expected impact

minimal upward pressure as a confidence signal, but size is too tiny to move the stock.

Evidence & confidence

Insider buying by a CEO can be positive, yet $1k is trivial for a listed biotech; traders are unlikely to act.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The purchase may be a routine portfolio adjustment rather than a strong confidence signal.

Key entities

  • person
    Altman Peter

    President and CEO of BioCardia, Inc.

  • company
    BioCardia, Inc.

    US-listed biotech company (ticker BCDA).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCDA insider trading history →

Related articles

OCT 19
$BCDAMedAI 8/10

BioCardia Advances Helix Catheter Toward FDA Marketing Clearance

BioCardia (BCDA) submitted a revised De Novo pre-submission package to the FDA for its Helix catheter, following feedback. The FDA accepted the submission and expects review, feedback, and a meeting in Q4 2026. The catheter is designed for delivering therapeutic agents to heart muscle and has clinical safety data from 15 trials. FDA clearance could expand partnership opportunities for BCDA.

rttnews.com2 min
OCT 19
$BCDAHighAI 8/10

BioCardia: FDA Accepts De Novo Pre-Submission for Helix Catheter; Substantive Review, Meeting Expected This Quarter

BioCardia's FDA pre-submission for Helix catheter was accepted, with substantive review and a meeting expected this quarter. The FDA raised no concerns about safety or performance. The company has clinical data from 15 trials supporting potential clearance, which could expand partnerships. According to the company, marketing clearance could enhance opportunities with cardiac biologics developers.

tradingview.com1 min
OCT 19
$BCDAMedAI 8/10

FDA accepts BioCardia pre-submission for Helix catheter

BioCardia Inc. (BCDA) announced the FDA accepted its pre-submission for the Helix catheter, a device for heart agent delivery. The FDA indicated two pathways for clearance and raised no safety concerns. BioCardia expects substantive review and feedback this quarter. The Helix catheter is supported by clinical data from 15 trials with nearly 500 patients.

investing.com2 min
OCT 19
$BCDAHighAI 8/10

BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for HelixTM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected…

BioCardia, Inc. (BCDA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix TM Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter October 19, 2026, Sunnyvale, Calif. BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular an

SEC EDGAR 8-K2 min